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Allogeneic Among the late effects of hematopoietic stem cell transplantation (HSCT), chronic graft-vs-host disease (cGVHD) still remains as the major determinant of long-term outcome and quality of life. The disease typically appears between 3 months to 1.5 years following an allogeneic transplantation and is characterized by symptoms similar to those of autoimmune disease.
GVHD is caused by donor CD4 and CD8 T cell-mediated anti-host reaction that evolves over several weeks to months, suggesting a requirement for persistent alloreactive T cells.
It has recently been demonstrated that donor-derived, alloreactive CD4 T cells play an important role in the pathogenesis of cGVHD that might be associated with a preponderance of CD4 effector memory cells (CCR7
Comparatively little is known about the role of CD8 T cells in cGVHD and whether, similarly to CD4 T cells, it is associated with the preponderance of a particular CD8 T-cell subset.
Human CD8 T cells can be divided into at least four different subsets, based on their phenotype and functions: naive (T naive , CCR7 In order to assess the balance between memory and effector cells and analyze the distribution of CD8 T cells within the four previously described subsets, we have studied peripheral blood samples from cGVHD patients.
In total, 20 adult patients, affected by various hematologic malignancies and treated by allogeneic peripheral blood stem cell (aPBSC) transplantation from HLA-identical related donors, were recruited for this study.
Ten of them had cGVHD and 10 patients had no current cGVHD (4100 days after transplantation). In the group of patients with cGVHD, three had extensive and seven limited disease. A great proportion of patients with cGVHD required immunosoppressive treatment at the time of sampling. Ten patients who underwent kidney transplantation (KT) requiring treatment with immunosuppressive drugs were used as controls for the effects of immunosuppressive drugs. Fifteen age-and sexmatched normal healthy subjects (HS) were used as controls.
Patients showing infection at the time of the study were not included. The study was approved by the Institutional Review Board.
Fresh peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll separation (Cedarlane, Ontario, CA, USA).
Cells were stained with quantum-red (QR)-conjugated antihuman CD8 monoclonal antibody (mAb) (Sigma), phycoerythryn (PE)-conjugated anti-human CCR7 mAb, fluorescein isothiocyanate (FITC)-conjugated antihuman CD45RA mAb and FITC-conjugated anti-human perforin mAb, all from BD Biosciences (San Diego, CA, USA). PE-conjugated Prot Pentamer H-Y A2 was from ProImmune (Oxford, UK). mAbs were used following the manufacturer's recommendations. Perforin expression was assessed after fixation with 2% paraformaldehyde and permeabilization with permeabilizing solution (BD Biosciences).
Flow cytometry was performed using a FACSCan flow cytometer (BD Biosciences) and analysis was performed with WinMDI 2.8 software.
Two-group comparison was carried out on the analysis of variance and Student's t-test. A P-value less than 0.05 was considered statistically significant. Data were analyzed using the SYSTAT 11 software.
CCR7 and CD45RA expression was analyzed on CD8 T cells from patients who received aPBSC transplantation both with and without cGVHD and healthy subjects. Additionally, as all cGVHD patients were receiving immunosuppressive treatment at the time the blood samples were collected, we also analyzed CD8 T-cell subsets in patients receiving cyclosporine A (CsA) and steroids treatment following KT in order to evaluate the impact of immunosuppressive drugs on CD8 subsets. Table 1 shows a significant reduction of CD8 T naive cells in patients with cGVHD, compared with stem cell transplantation patients without cGVHD (P ¼ 0.008), with patients who underwent KT (P ¼ 0.006) and with healthy subjects (P ¼ 0.008). The T CM subset was also decreased in cGVHD patients, but the values' difference in patients without cGVHD, kidney transplated and healthy subjects was not statistically significant. Effector CD8 T cells' distribution showed no statistically significant difference in the T EM subset in the tested groups, but patients with cGVHD had a significantly higher percentage of T EMRA cells, compared with stem cell transplantation patients without cGVHD (respectively; P ¼ 0.003), with patients who underwent KT (P ¼ 0.004) and with healthy subjects (P ¼ 0.005).
These results suggest that the decrease of the T naive and the strong increase of the T EMRA CD8 T-cell subsets are a peculiarity of cGVHD and are not an effect of immunosuppressive drugs administration.
Previous studies showed that CD45RA þ T EMRA cells express high levels of perforin notably associated with CCR7 downregulation, as the acquisition of cytotoxicity properties is paralleled with loss of lymph node homing ability. 2 Accordingly, we detected increased perforin levels in CD8 CCR7
À cells from cGVHD patients (38.8%715.4) compared with patients without GHVD (12.5%75.9) and healthy subject (10.4%75.4).
These data are consistent with previous studies showing increasing perforin gene expression by quantitative RT-PCR in GVHD patients. 3 As in HLA-identical transplantation GVHD may be induced by minor histocompatibility antigen (mHags) differences between the donor and the recipient, with the antigen being present in the recipient and not in the donor, we analyzed the distribution of CD8 T lymphocyte subsets specific for the male-related mHag H-Y in PBMCs from two HLA-A0201 male patients in whom cGVHD occurred and who received transplant from an HLA-identical female sibling. Previous studies have reported that H-Y is a target of cytotoxic T lymphocytes (CTLs) in GVHD, as demonstrated using a skinexplant assay and tetrameric HLA-mHag peptide complexes, 4 and, in particular, there is evidence for the priming of CD8 T-cytotoxic lymphocytes against H-Y antigen. 5 As shown in Figure 1a , the frequency of H-Y-specific CD8 T lymphocytes, as detected by staining with an H-Y A2 pentamer, in these two patients is notably higher (4.7 and 2.16%, respectively) than the frequency in a non-HLA-A0201 male patient receiving transplant from an identical female donor (0.06%). In both patients, the vast majority of pentamer þ CD8 T cells were CD45RA þ CCR7 À (Figure 1b) , thus confirming in an alloantigen-specific system the skewed distribution of CD8 T-cell subset observed in the whole CD8 population.
Thus, our data represent the first demonstration of a correlation between the increase of T EMRA subset in CD8 T cells and the occurrence of cGVHD in patients who underwent a PBSC transplantation.
Although it is possible that reduction in size of the T naive and T CM CD8 subsets in cGVHD might be the consequence of the reduced production of naive recent thymic T-cell emigrants and/ Letters to the Editor or impaired survival in the periphery, 6 the mechanisms leading to the increase of CD8 T EMRA cells are unknown.
As Activating mutations of genes in the receptor tyrosine kinase RAS-BRAF (RTK/RAS-BRAF) signal transduction pathway are common in myelodysplasia (MDS) and acute myeloid leukemia (AML) [1] [2] [3] [4] and in the therapy-related subsets of these diseases (t-MDS/t-AML). 5 Recently, a specific activating mutation of the JAK2 tyrosine kinase was detected in 154/201 cases of polycythemia vera (77%), in 21/44 cases of idiopatic myelofibrosis (48%) and in 50/144 cases of essential thrombocythemia (35%). 6, 7 The JAK2V617F mutation was subsequently observed only sporadically in 3/119 cases of chronic myelomonocytic leukemia, including a case with a history of B cell lymphoma, and in 5/101 cases of MDS including four patients with a normal karyotype. 8 In our systematic search for genetic abnormalities in t-MDS and t-AML and their association to clinical parameters and cytogenetic characteristics, we examined 140 unselected patients with t-MDS or t-AML previously examined for mutations in the RTK/RAS-BRAF pathway 5 for the JAK2V617F mutation. PCR amplification and direct sequencing of JAK2 exon 12 was performed as previously reported 5 using primers described elsewhere. Direct DNA sequence analysis of JAK2 exon 12. At the top, a wild-type sequence from a normal control is shown for comparison. The middle sequence shows equal fluorescence intensities of the mutated and the wild-type alleles in patient 43, whereas at the bottom the sequence of the wild-type allele of patient 179 is only faintly visible.
